Products

What will AGI do for Blonanserin?

This classification denotes a serotonin antagonist with the molecular formula C23H30FN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, AQ316B4F8C chemically known as 2-(4-ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine but generally known as blonanserin, which bears US NIH Compound Identifier 125564. European Medicines Agency schedules Blonanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05864MIG. The term BLONANSERIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 11, no. 3 1997, list 38. ). Most nations schedule blonanserin under HS 29335995 and SITC 51576. As of Q4 2014, BLONANSERIN remains the US FDA Preferred Term for this commodity. Blonanserin bears US NLM identifiers UMLS ID C0287983 and NCI Concept Code C95920. SMILES: CCN1CCN(CC1)C2=NC3=C(CCCCCC3)C(=C2)C4=CC=C(C=C4)F.

How AGI delivers it

Four ways AGI delivers for Blonanserin

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Blonanserin, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Blonanserin, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Blonanserin connects

measured by

  • Active Ingredient Assaymodel
  • Assay Puritymodel
  • Content Uniformitymodel
  • Dissolution Ratemodel
  • Particle Size Distributionmodel
  • Polymorph Formmodel
  • Residual Solventmodel
  • Tablet Hardnessmodel